Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials CRM IHD Neuroscience Oncology Ophthalmology Respiratory Sandoz Biopharmaceuticals Global Health Abbreviations LNP023 - Factor B inhibition of the complement alternative pathway Study Indication Phase Patients Primary Outcome Measures NCT04817618 APPEAR-C3G (CLNP023B12301) C3 glomerulopathy Phase 3 68 Log-transformed ratio to baseline in UPCR (sampled from a 24 hour urine collection) Arms Intervention Target Patients Experimental: iptacopan 200mg b.i.d. Placebo Comparator: Placebo to iptacopan 200mg b.i.d. Patients with native C3G Read-out Milesstone(s) 2023 Publication TBD 68 Investor Relations | Q2 2021 Results NCT04820530 APPOINT-PNH (CLNP023C12301) Paroxysmal nocturnal haemoglobinuria Phase 3 40 Proportion of participants achieving a sustained increase from baseline in hemoglobin levels of ≥2 g/dL assessed, in the absence of red blood cell transfusions Iptacopan (LNP023), taken orally b.i.d. (dosage supplied: 200mg) PNH patients who are naive to complement inhibitor therapy, including anti-C5 antibody 2023 TBD NOVARTIS | Reimagining Medicine

View entire presentation